HALE DAVID F - 06 Oct 2022 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role
Director
Signature
/s/ Gerald T. Proehl, Attorney-in-Fact
Issuer symbol
DRMA
Transactions as of
06 Oct 2022
Net transactions value
$0
Form type
4
Filing time
07 Oct 2022, 17:06:06 UTC
Previous filing
08 Jul 2022
Next filing
30 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRMA Common Stock Award $0 +30,155 +66% $0.000000 75,720 06 Oct 2022 Direct F1
holding DRMA Common Stock 12,195 06 Oct 2022 By Hale Trading Company L.P. F2
holding DRMA Common Stock 35,714 06 Oct 2022 By Hale Family Trust
holding DRMA Common Stock 532,925 06 Oct 2022 By Hale BioPharma Ventures LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 6, 2022, the Reporting Person was granted 30,155 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
F2 Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.